✦ LIBER ✦

Pharmacology of the human metabolites of dolasetron, an antiemetic 5-HT3 receptor antagonist

✍ Scribed by Marc Bigaud; Jack Elands; Philip R. Kastner; Rick A. Bohnke; Lee W. Emmert; Martin Galvan

Publisher: John Wiley and Sons
Year: 1995
Tongue: English
Weight: 699 KB
Volume: 34
Category: Article
ISSN: 0272-4391
DOI: 10.1002/ddr.430340306

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacological properties of dolasetron

Pharmacological properties of dolasetron, a potent and selective antagonist at 5-HT3 receptors

✍ Robert C. Miller; Martin Galvan; Maurice W. Gittos; Paul L. M. van Giersbergen; 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 626 KB

Zatosetron, a selective 5-HT3 receptor a

Zatosetron, a selective 5-HT3 receptor antagonist: Pharmacological activities of human and animal metabolites

✍ Marlene L. Cohen; William Bloomquist; Christopher R. Schmid; David W. Robertson; 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 555 KB

## Abstract Zatosetron is a potent, orally active 5‐HT~3~ receptor antagonist with a long duration of activity in laboratory animals and humans. Several metabolites have been detected in plasma and urine of humans and experimental animals receiving zatosetron. The present study was designed to expl

From Cocaine to Innovative Antiemetics.

From Cocaine to Innovative Antiemetics. Medicinal Chemistry of 5-HT3 Receptor Antagonists

✍ Heiko Zettl; Manfred Schubert-Zsilavecz; Carsten D. Siebert 📂 Article 📅 2007 🏛 John Wiley and Sons ⚖ 11 KB

L-683,877: Pharmacological profile of a

L-683,877: Pharmacological profile of a novel 5-HT3 receptor antagonist

✍ Dr. David Tattersall; Nigel Newberry; Margaret S. Beer; Mike Rigby; Michael Gilb 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 731 KB

Serotonin receptor diversity in the huma

Serotonin receptor diversity in the human colon: Expression of serotonin type 3 receptor subunits 5-HT3C, 5-HT3D, and 5-HT3E

✍ Johannes Kapeller; Dorothee Möller; Felix Lasitschka; Frank Autschbach; Ruud Hov 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 723 KB

Improved prevention of moderately emetog

Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist : Results of a Phase III, single-dose trial versus dolasetron

✍ Peter Eisenberg; Jazmin Figueroa-Vadillo; Rosalio Zamora; Veena Charu; Julio Haj 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 174 KB

## Background: Palonosetron, a highly selective and potent 5-ht(3) receptor antagonist with a strong binding affinity and a long plasma elimination half-life (approximately 40 hours), has shown efficacy in phase ii trials in preventing chemotherapy-induced nausea and vomiting (cinv) resulting from